

Generation Study 2

Summary of Brain Amyloid Test Result

This fact sheet summarizes your brain amyloid test result. You received this test as part of your participation in Generation Study 2 (CNP520A2202J). If you have any questions about this information, please contact _____.

➤ Your amyloid level was measured by:

PET Scan Lumbar Puncture

Date of Test: _____

➤ Your brain amyloid test result was:

Elevated Not Elevated Not Disclosed

Amyloid Test Summary Points

- This amyloid test was done as part of screening for Generation Study 2 (CNP520A2202J). For participants who have one copy of the APOE4 gene, this is one of the tests used to determine eligibility.
- Having elevated amyloid may increase the risk of developing dementia due to Alzheimer's disease.
 - Elevated amyloid does not mean a person will definitely develop dementia due to Alzheimer's disease.
- Even if a person's amyloid level is not elevated, amyloid may still be present, just not at an elevated level.
 - A person who has a not elevated amyloid level could have an elevated level in the future.
 - A person who has a not elevated level could still develop dementia due to Alzheimer's disease in the future.
- Brain amyloid tests only evaluate the presence of amyloid at the time these tests are done.
- The test result cannot determine whether you will develop dementia due to Alzheimer's disease now or in the future.
- At present, researchers and clinicians do not have enough information to use a person's amyloid test result to estimate their risk of developing dementia due to Alzheimer's disease.
 - This also means we cannot combine amyloid and APOE test results to estimate risk for developing dementia due to Alzheimer's disease.

Cristina Lopez Lopez, Pierre N. Tariot, Angelika Caputo, Jessica B. Langbaum, Fonda Liu, Marie-Emmanuelle Riviere, Carolyn Langlois, Marie-Laure Rouzade-Dominguez, Martin Zalesak, Suzanne Hendrix, Ronald G. Thomas, Vissia Viglietta, Rob Lenz, J. Michael Ryan, Ana Graf, Eric M. Reiman. The Alzheimer's Prevention Initiative Generation Program: Study design of two randomized controlled trials for individuals at risk for clinical onset of Alzheimer's disease. *Alzheimer's & Dementia: Translational Research & Clinical Interventions*. 2019 5; 216-227. doi.org/10.1016/j.trci.2019.02.005.

The Generation Program was funded by Novartis and Amgen, in collaboration with the Banner Alzheimer's Institute. Generation Study 1 was supported by funding from the National Institute on Aging (1UF1AG046150), part of the National Institutes of Health, as well as the Alzheimer's Association, FBRI, GHR Foundation and Banner Alzheimer's Foundation.